ENTPD1 and neoplasm: Tumor‐infiltrating CD8+ T cells exhibited reduced exhaustion markers (CD39, LAG‐3 under YD monotherapy) and increased proliferation/activation (Ki‐67 and CD25) (Figure S7d, Supporting Information).